MedTrace Logo

RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.

NCT05180357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 273

Last updated 2023-04-19

No results posted yet for this study

Summary

The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.

Conditions

  • Severe Eosinophilic Asthma
  • Nasal Polyps

Interventions

OTHER

FASENRA(benralizumab)

This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-23
Primary Completion
2022-10-28
Completion
2022-10-28

Countries

  • United States
  • France
  • Germany
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180357 on ClinicalTrials.gov